Combination of tyrosine kinase inhibitor and chemical castration

Details Combination of tyrosine kinase inhibitor and chemical castration Combination of tyrosine kinase inhibitor and chemical castration

1998-08-13

1999-11-16

Krass, Frederick

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

514 2, 514 16, 514 17, 514170, 514171, 514211, 514249, 514279, 514338, 514339, 514410, A61K 4506, A61K 3155

Patent

active

059858770

ABSTRACT:
A method of treating prostate cancer by co-administering a tyrosine kinase inhibitor such as an indolocarbazole and a chemical castration agent is disclosed. A composition containing a tyrosine kinase inhibitor and a chemical castration agent is also disclosed.

REFERENCES:
patent: 4659695 (1987-04-01), Labrie
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5461146 (1995-10-01), Lewis et al.
patent: 5475110 (1995-12-01), Hudkins et al.
patent: 5516771 (1996-05-01), Dionne et al.
patent: 5591855 (1997-01-01), Hudkins et al.
patent: 5594009 (1997-01-01), Hudkins et al.
patent: 5650407 (1997-07-01), Mallamo et al.
patent: 5654427 (1997-08-01), Dionne et al.
patent: 5659407 (1997-08-01), Andersen et al.
patent: 5789427 (1998-08-01), Chen et al.
George et al., "Combined Effects of the Trk Tyrosine Kinase Inhibitor, EP-751 (KT-6587), and Castration on . . . ", Proceedings of American Assoc for Cancer Res. Annual Meeting, 39:664 XP002092523, 1998.
Dionne et al., "Inhibition of Prostate Tumor Growth by the Trk-selective Tyrosine Kinase Inhibitor, CEP-751 (KT-6587)", Proceedings of American Assoc. for Cancer Research Annual Meeting 38:634 XP002092524, 1997.
Lavelle, "Tyrosine Protein Kinase Inhibitors in Oncology: The End of the Beginning?", Bull. Cancer 84:769-770, 1997, Translation.
Camoratto et al., "CEP-751 Inhibits TRK Receptor Tyrosine Kinase Activity In Vitro and Exhibits and Anti-Tumor Activity", Int. J. Cancer 72:673-679, 1997.
Crawford et al., "A Controlled Trial of Leuprolide With and Without Flutamide in Prostatic Carcinoma", The New England Journal of Medicine 321:419-424, 1989.
Dionne et al., "Cell Cycle-independent Death of Prostate Aenocarcinoma is Induced by the trk Tyrosine Kinase Inhibitor CEP-751 (KT6587)", Clinical Cancer Research 4:1887-1898, 1998.
Isaacs et al., "Adaptation versus Selection as the Mechanism Responsible for the Relapse of Prostatic Cancer to Androgen Ablation Therapy as Studied in the Dunning R-3327-H . . . ", Cancer Res. 41:5070-5075, 1981.
Isaacs, "Relationship between Tumor Size and Curability of Prostatic Cancer by Combined Chemo-Hormonal Therapy in Rats", Cancer Research 49:6290-6294, 1989.
Parker et al., "Cancer Statistics, 1996", CA Cancer J. Clin. 65:5-27, 1996.
Tapley et al., "K252a is a Selective Inhibitor of the Tryosine Protein Kinase Activity of the trk Family of Oncogenes and Neurotropin Receptors", Oncogene 7:371-381, 1992.
Zaccheo et al., "Effect of Turosteride, a 5a-Reductase Inhibitor, on the Dunning R3327 Rat Prostatic Carcinoma", The Prostate 30:85-91, 1997.

Affiliated with

Also associated with

Rating

Combination of tyrosine kinase inhibitor and chemical castration does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination of tyrosine kinase inhibitor and chemical castration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of tyrosine kinase inhibitor and chemical castration will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1325009